Studies show that SDB is an independent risk factor for cardiovascular disease, and can place a patient at higher risk for stroke and sudden cardiac death. With one in three people who have high blood pressure also suffering from sleep apnea, there is a strong connection between the two. Sleep apnea is strongly linked with hypertension, regardless of other risk factors. Studies show that treating sleep apnea can lower blood pressure and benefit overall heart health.
SERVE-HF, sponsored by ResMed, is the largest randomized controlled study in the field of sleep-disordered breathing and heart failure. The trial is assessing the benefits of PaceWave™ adaptive-servo ventilation (ASV) therapy on patients with chronic heart failure. ASV treats complex sleep apnea syndrome and central sleep apnea by automatically calculating how much pressure a patient requires on a breath-by-breath basis. The study comprises 1,325 patients in 80 centers across Europe and Australia. It focuses on time to death, the impact of treatment on healthcare economics, quality of life, overall cardiac function, and the impact on unplanned heart-failure related hospitalizations. Results, expected in 2016, could have a major impact on the future management of heart failure patients.
 Gami et al. Obstructive sleep apnea and the risk of sudden cardiac death. A longitudinal study of 10,701 adults. J Am Coll Cardiol 2013;62(7):610-616.
 Fava et al. Effect of continuous positive airway pressure (CPAP) on blood pressure in patients with obstructive sleep apnea/hypopnea. A systematic review and meta-analysis. Chest 2013.